Horizon Pharma plc (HZNP) Boosts FY16 Sales, adj.-EBITDA Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St set to open higher as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil slides as US-Iran truce hopes outweigh Houthi attacks on Saudi Arabia
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Mizuho Securities Remains Bullish as Horizon Pharma (HZNP) Updates Guidance to Include Krystexxa
January 12, 2016 10:09 AM ESTMizuho Securities reiterated a Buy rating and $36.00 price target on Horizon Pharma (NASDAQ: HZNP) following managements indication that company's $75M guidance raise is only for the inclusion of Krystexxa.
Analyst Irina Koffler commented, "The HSR waiting period on the Crealta acquisition expired on January 11 and... More
